Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Income from Non-Controlling Interests (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Income from Non-Controlling Interests for 4 consecutive years, with -$712.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Non-Controlling Interests changed 0.14% to -$712.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$6064.0, a 84.29% increase, with the full-year FY2024 number at -$8556.0, up 82.21% from a year prior.
  • Income from Non-Controlling Interests was -$712.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$752.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $2527.0 in Q1 2023 to a low of -$33933.0 in Q4 2023.
  • A 4-year average of -$5367.2 and a median of -$2801.0 in 2022 define the central range for Income from Non-Controlling Interests.
  • Peak YoY movement for Income from Non-Controlling Interests: tumbled 204.41% in 2023, then skyrocketed 92.62% in 2024.
  • 60 Degrees Pharmaceuticals' Income from Non-Controlling Interests stood at -$3172.0 in 2022, then plummeted by 969.77% to -$33933.0 in 2023, then skyrocketed by 88.55% to -$3887.0 in 2024, then surged by 81.68% to -$712.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Income from Non-Controlling Interests are -$712.0 (Q3 2025), -$752.0 (Q1 2025), and -$3887.0 (Q4 2024).